LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

38.06 4.56

Overview

Share price change

24h

Current

Min

36.31

Max

38.4

Key metrics

By Trading Economics

Income

33M

-48M

Sales

-2.6M

106M

EPS

-0.45

Profit margin

-45.487

Employees

1,869

EBITDA

19M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.15% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

36M

3.4B

Previous open

33.5

Previous close

38.06

News Sentiment

By Acuity

23%

77%

44 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2025, 20:45 UTC

Earnings

Broadcom 2Q Sales Climb on Booming AI Demand

5 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 Jun 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 Jun 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 Jun 2025, 21:32 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 20:45 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:24 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Rev $15B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Net $4.97B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $1.58 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom Sees 3Q Rev $15.8B >AVGO

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 Jun 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 Jun 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 Jun 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 Jun 2025, 18:26 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 Jun 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 Jun 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 Jun 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 Jun 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

34.15% upside

12 Months Forecast

Average 48.4 USD  34.15%

High 56 USD

Low 32.6 USD

Based on 6 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

44 / 380 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.